-
Analyst Opinions
NewEvolution of Clean Label in Household Care and Laundry – Industry Insights
This report investigates the rise of clean label and its implications for brands and consumers. Clean label attributes are increasingly demanded by eco-concious and ethically-minded consumers, and often span health, environmental, and ethical factors.
-
Product Insights
NewLikelihood of Approval Analysis for Obstructive Sleep Apnea
Overview How likely is it that the drugs in Obstructive Sleep Apnea will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obstructive Sleep Apnea Overview Obstructive sleep apnea (OSA) is defined by...
-
Product Insights
NewLikelihood of Approval Analysis for Rheumatoid Arthritis
Overview How likely is it that the drugs in Rheumatoid Arthritis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rheumatoid Arthritis Overview Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized...
-
Analyst Opinions
NewMobile World Congress (MWC) 2024 – Startups Race for Digital Change
Mobile World Congress (MWC) 2024 Report Overview MWC (Mobile World Congress) is a premier global event for the mobile technology industry, while 4YFN (4 Years from Now) is its associated platform focusing on connecting startups with investors and partners to drive innovation. With over 40 companies in attendance, AI startups took center stage at MWC 2024, signaling robust investor and market interest in AI as the key driver for future innovation. Beyond AI, fintech, digitalization, IoT, digital media, and health...
-
Thematic Analysis
NewGeopolitics – Executive Briefing (First Edition)
Reasons to buy the ‘Geopolitics - Executive Briefing’ report: The report provides in-depth insights into the global geopolitical stance. Explore a global geopolitical risk map highlighting level of severity and a summary on the 2024 elections. Identify the frontline sectors exposed to global geopolitics. The report sheds light on the politics of the major countries that shape geopolitics. How is the ‘Geopolitics - Executive Briefing’ report different from other reports in the market? This executive briefing report explores the drivers...
-
Thematic Analysis
NewUkraine Conflict Impact – Thematic Intelligence
Ukraine Conflict Impact Report Overview The large-scale Russian invasion of Ukraine in February 2022 has dramatically restructured strategic priorities within the global defense sector either by developing innovative defense capabilities, or the re-invigorating previously stagnant market segments. As the geostrategic implications of this conflict continue to reverberate across global markets, the primary lesson learned is the need to upscale production capacity and leverage cost-efficiency across all domains of modern warfare, with investments driving innovation of both technology and operations throughout...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BDTX-1535 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDTX-1535 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDTX-1535 in Glioblastoma Multiforme (GBM) Drug Details: BDTX-1535 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDTX-1535 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDTX-1535 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDTX-1535 in Non-Small Cell Lung Cancer Drug Details: BDTX-1535...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDTX-1535 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDTX-1535 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDTX-1535 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: BDTX-1535...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Follicular Lymphoma Drug Details: Tipifarnib (Zarnestra) is under development for...